XOFIGO Solution for injection Ref.[9648] Active ingredients: Radium-223 dichloride

Source: European Medicines Agency (EU)  Revision Year: 2020  Publisher: Bayer AG, 51368, Leverkusen, Germany

Product name and form

Xofigo 1100 kBq/mL solution for injection.

Pharmaceutical Form

Solution for injection.

Clear, colourless isotonic solution with pH between 6.0 and 8.0.

Qualitative and quantitative composition

Each mL of solution contains 1100 kBq radium Ra 223 dichloride (radium-223 dichloride), corresponding to 0.58 ng radium-223 at the reference date. Radium is present in the solution as a free ion.

Each vial contains 6 mL of solution (6.6 MBq radium-223 dichloride at the reference date).

Radium-223 is an alpha particle-emitter with a half-life of 11.4 days. The specific activity of radium-223 is 1.9 MBq/ng.

The six-stage-decay of radium-223 to lead-207 occurs via short-lived daughters, and is accompanied by a number of alpha, beta and gamma emissions with different energies and emission probabilities. The fraction of energy emitted from radium-223 and its daughters as alpha-particles is 95.3% (energy range of 5.0-7.5 MeV). The fraction emitted as beta-particles is 3.6% (average energies are 0.445 MeV and 0.492 MeV), and the fraction emitted as gamma-radiation is 1.1% (energy range of 0.01-1.27 MeV).

Figure 1. Radium-223 decay chain with physical half-lives and mode of decay:

Excipients with known effect: Each mL of solution contains 0.194 mmol (equivalent to 4.5 mg) of sodium.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Radium-223 dichloride

Radium-223 dichloride mimics calcium and selectively targets bone, specifically areas of bone metastases, by forming complexes with the bone mineral hydroxyapatite. Radium-223 dichloride monotherapy or in combination with luteinising hormone releasing hormone (LHRH) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).

List of Excipients

Water for injections
Sodium citrate
Sodium chloride
Hydrochloric acid, dilute

Pack sizes and marketing

Colourless Type I glass vial closed with a grey bromobutyl rubber stopper either with or without foil-clad made of Ethylene tetrafluoroethylene (ETFE), both capped with aluminium seal, containing 6 mL of solution for injection.

The vial is stored in a lead pot.

Marketing authorization holder

Bayer AG, 51368, Leverkusen, Germany

Marketing authorization dates and numbers

EU/1/13/873/001

Date of first authorisation: 13 November 2013
Date of latest renewal: 21 June 2018

Drugs

Drug Countries
XOFIGO Austria, Brazil, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Poland, Singapore, Turkey, United Kingdom, United States, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.